[en] Purpose: The effectivenes of maintenance treatment with PARP inhibitor olaparib in platinum-sensitive recurrent serous, papillary, high-grade carcinoma of the left adnexais presented. Case report: We describe the case report of a cacer patient who was 43 year sold at thetime of diagnosis. After 36 months, a platinumsensitive relapse of a serous, papillary, high-grade tumor of left adnexawas confirmed. The patient was treated with 2-line palliative chemotherapy paclitaxel, carboplatina (7 cycles) and subsequently treated with maintenance treatmet with olaparib untilnow. The basic diseaseis in complete remission. Conclusion: Olaparib is the first PARP inhibitorisindicated as maintenance therapy in patients with BRCA mutations, with newly diagnosed advanced ovarian cancer and also in patients with platinum-sensitive recurrent ovarian cancer who have achieved a terapeutic response to platinm-based chemotherapy. (author)